A suffocating CD20 antigen, rich in 60 or less of the trace gases in ASN297, was used to treat cancer in combination with Bendamistina.

摘要

The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody with bendamustine for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Ly1 antibody and bendamustine.